ImmunoGen, Inc. (NASDAQ:IMGN)
The Company develops antibody-based anticancer therapeutics.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Safetymatt
(< 20)
Submitted: 4/23/2013 12:24:28 AM :
Start Price:
$14.74
IMGN Score:
+10.13
Been watching for a while and like the potential possibilities. Gambling on IMGN
Recs
usubanas
(99.50)
Submitted: 4/12/2013 12:46:00 PM :
Start Price:
$16.01
IMGN Score:
-0.91
Feels strange to red-thumb IMGN after so many years of owning it. But now they depend more on their internal pipeline development to justify their valuation, and certainly are not very good at it.
Recs
ElRemaro
(93.45)
Submitted: 3/31/2013 10:00:34 AM :
Start Price:
$16.02
IMGN Score:
-0.36
TMFUltraLong
Recs
zzlangerhans
(99.77)
Submitted: 2/27/2013 1:38:33 AM :
Start Price:
$14.74
IMGN Score:
-4.04
There's no question that the approval of T-DM1 for metastatic breast cancer is a great accomplishment for ImmunoGen. Where the company has fallen short is in the deal they made with Roche, in which their royalties will be only 3% of revenues up to 700M and then 5% after that. T-DM1 may become a multibillion dollar drug eventually but revenues will have to be 2.3 billion per year before ImmunoGen sees 100M of it. That potential and some phase I candidates don't justify a billion dollar enterprise value in my mind. ImmunoGen seems ripe for a pullback to levels closer to 12 seen at the beginning of 2013.
Recs
bychen
(< 20)
Submitted: 1/22/2013 11:11:45 AM :
Start Price:
$15.68
IMGN Score:
-4.05
The technology is bearing fruit and could be applied to multiple cancers.
Recs
Agabone
(< 20)
Submitted: 1/14/2013 8:22:35 PM :
Start Price:
$14.65
IMGN Score:
+2.07
Immunogen's proprietary TAP technology is licensedto Genentech for their groundbreaking drug for HER2-positive metastatic breast cancer. This drug looks all set for approval within the very near future and its clinical trials data show significant increases in overall survival. This is a treatment that has the potential to transform the eway we treat breast cancer and has implications for other tumor types, too. When the drug is approved, the money will start to roll in for Immunogen.
Recs
genedom
(98.34)
Submitted: 10/30/2012 2:18:55 AM :
Start Price:
$11.52
IMGN Score:
+30.06
Value at this price.
Recs
GOGCwatch07
(88.24)
Submitted: 10/1/2012 3:52:15 PM :
Start Price:
$14.86
IMGN Score:
-1.19
CEO just bought 180,000 call options with a strike price at $15.83
Recs
HIGHG33K
(75.41)
Submitted: 9/13/2012 11:22:15 AM :
Start Price:
$14.56
IMGN Score:
+1.39
Undervalued comparing with SGEN
Recs
MicroMagic
(56.14)
Submitted: 8/31/2012 7:02:48 PM :
Start Price:
$14.43
IMGN Score:
-0.96
I like their pipeline, there's no specific catalyst, that I'm aware of to pick this baby now. Perhaps in 5 years this will be more than a multibagger.
I like the chances with this one.
Recs
etbean
(66.38)
Submitted: 8/7/2012 4:20:44 PM :
Start Price:
$13.10
IMGN Score:
+10.56
just watching it go down. Will buy around 8$
Recs
talia123
(< 20)
Submitted: 3/30/2012 9:44:05 AM :
Start Price:
$15.06
IMGN Score:
-5.70
It only take 1 good drug
Recs
kmv98finance
(34.94)
Submitted: 1/31/2012 12:56:29 PM :
Start Price:
$14.14
IMGN Score:
-7.04
This is a great company based on a solid science foundation. It's platform is proving to work. Not only did TDM1 have phenomenal phase 2 results, but its partnerships with other companies are also doing very well. This indicates a lot more future value when these products get through development. I see this as a buy and anticipate the company will be acquired someday...hopefully by Roche.
Recs
thomluc3
(< 20)
Submitted: 10/1/2011 3:36:01 PM :
Start Price:
$10.83
IMGN Score:
+8.76
Good approach to cancer therapy. A step away from traditional chemotherapy. Any breakthrough in adenocarcinoma tumor therapy will lead to application for prostate carcinoma. We have not had any real therapeutic breakthrough in a long time. The tools are now in the workshop!
Recs
gopyerk
(83.55)
Submitted: 9/27/2011 9:47:10 AM :
Start Price:
$11.58
IMGN Score:
+6.55
Phase 2 clinical trials of cancer drug were characterized as striking, CEO claims Phase three trials may be done by 2014. I just like all the news so I will take a flyer...
Recs
Kreddo
(< 20)
Submitted: 5/29/2011 7:01:00 PM :
Start Price:
$12.07
IMGN Score:
+16.72
Strong believe in lead drug
Recs
exchequer23
(< 20)
Submitted: 2/5/2011 12:45:09 PM :
Start Price:
$8.47
IMGN Score:
+74.42
Confidence in receipt of FDA approval
Recs
Mliaom
(48.95)
Submitted: 11/9/2010 5:03:21 PM :
Start Price:
$8.24
IMGN Score:
+65.66
I want my personal $ dedicated to this cause. I would root for any small bio co with the potential to make a significant difference in breast cancer treatment.
Recs
Philyogy
(< 20)
Submitted: 10/31/2010 10:16:11 PM :
Start Price:
$8.30
IMGN Score:
+64.87
buy... hold... 2013.................
Recs
TMFBreakerThiel
(78.08)
Submitted: 9/28/2010 12:49:27 PM :
Start Price:
$5.75
IMGN Score:
+150.12
Hammered because it failed to get an accelerated review from FDA on T-DM1. Does complicate things, but doesn't bear on the efficacy of the drug, which looks strong in HER-2 pos breast cancer that has failed other treatments.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 40 : 1 2 Next »